Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Ovarian Neoplasms

Free Subscription 07.04.2025 3 Cancer Res 1 Eur J Obstet Gynecol Reprod Biol 1 Gynecol Oncol 1 Int J Cancer 1 Lancet Oncol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Cancer Res

1. HOUSE NC, Brown VE, Chen M, Yuan L, et al
   Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors.
   Cancer Res. 2025 Feb 13. doi: 10.1158/0008-5472.CAN-24-2360.
   PubMed         Abstract available
   
   
2. DOMMER AP, Kumarasamy V, Wang J, O'Connor TN, et al
   Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222.
   Cancer Res. 2025;85:1310-1326.
   PubMed         Abstract available
   
   
3. STOJANOVIC L, Abbotts R, Tripathi K, Coon CM, et al
   ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.
   Cancer Res. 2025;85:1183-1198.
   PubMed         Abstract available
   
   

   
   Eur J Obstet Gynecol Reprod Biol

4. DICK A, Cohen N, Flamer Y, Shekel E, et al
   Sonographic features of ovarian malignancies in children and young adults - A case control study.
   Eur J Obstet Gynecol Reprod Biol. 2025;308:112-115.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

5. HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
   MUTYH: Possibly another important gene in ovarian cancer?
   Gynecol Oncol. 2025;196:59-61.
   PubMed        
   
   

   
   Int J Cancer

6. LUND E, Busund LR, Holden L
   Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
   Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
   PubMed         Abstract available
   
   

   
   Lancet Oncol

7. VAN GORP T, Moore KN, Konecny GE, Leary A, et al
   Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
   Lancet Oncol. 2025;26:503-515.
   PubMed         Abstract available
   
   

   
   PLoS One

8. BAO Q, Wang Z, Yang T, Su X, et al
   Curcumin induces mitochondrial dysfunction-associated oxidative DNA damage in ovarian cancer cells.
   PLoS One. 2025;20:e0319846.
   PubMed         Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.